Intracavernosal injection of aviptadil and phentolamine for refractory erectile dysfunction
The Journal of Sexual Medicine · 2025
DOI: 10.1093/jsxmed/qdaf067 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Sexual Medicine, 2025. Verfasst von Abdullah Al-Mitwalli und 8 weiteren Autor:innen. Beteiligte Einrichtung: University College London Hospital, Urology, London W1G 8PH, United Kingdom. Hauptthemen laut MEDLINE: Erectile Dysfunction, Phentolamine. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 19 Literaturangaben.
Abstract (Originalsprache)
Background
Intracavernosal injection (ICI), most commonly with alprostadil, is recommended for Phosphodiesterase 5 Inhibitors (PDE5i) nonresponders in erectile dysfunction (ED) treatment; however, its use can cause pain (12%) and priapism (1%).
Aim
We aimed to evaluate the efficacy of another ICI, Invicorp, and a combination of aviptadil with phentolamine mesylate (AvP), in contemporary practice.
Methods
We conducted a retrospective single-center analysis on patients referred for AvP because they developed intolerable Pain following Alprostadil ICI (group PA) or had Failed maximal dose (40 μg) of Alprostadil (group F). Self-administration was taught in a nurse-led clinic, followed by a 6-week telephone follow-up. Efficacy was evaluated at 3 months and was defined as resumption of penetrative sexual activity.
Results
Of these, 308 men were included in this study with a mean follow-up period of 13.3 months. All these patients had a trial of alprostadil ICI, 96% had failed PDE5i, 66% had trailed a vacuum erection device, and 36% had failed intraurethral alprostadil. Overall, 182 men (59%) found AvP ICI effective. Indications were 177 in the PA group and 131 in the FA group. Efficacy of AvP in the PA group was 76% and this compares to 36% in the FA group (P < .0001). The most common adverse event was facial flushing in 69 patients (22.5%). Ischemic priapism was reported in only one patient (0.3%). Clinical Implications AvP represents an effective and well-accepted second-line option for men who have experienced failure with most nonsurgical treatments for ED. Strengths and Limitations This is the largest and only study to outline the use of AvP ICI with clear distinguishing of efficacy rates for both patients who have failed conventional maximum dose alprostadil ICIs and those who developed pain from it. Limitations of this study include its retrospective design and lack of validated instruments to objectively assess erectile function.
Conclusion
Almost 60% of the participants with refractory ED were successfully managed through the administration of AvP.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- University College London Hospital, Urology, London W1G 8PH, United Kingdom.
- Division of Surgery and Interventional Sciences, University College London, London WC1E 6BT, United Kingdom.
ORCID-Profile: Abdullah Al-Mitwalli, Wai Gin Lee
Zitieren
APA
Al-Mitwalli, A., Holden, F., Di Giovanni, A., Gobbo, A., Shah, M., Chiriaco, G., Sangster, P., Ralph, D., & Lee, W. G. (2025). Intracavernosal injection of aviptadil and phentolamine for refractory erectile dysfunction. The Journal of Sexual Medicine. https://doi.org/10.1093/jsxmed/qdaf067
Vancouver
Al-Mitwalli A, Holden F, Di Giovanni A, Gobbo A, Shah M, Chiriaco G, et al. Intracavernosal injection of aviptadil and phentolamine for refractory erectile dysfunction. The Journal of Sexual Medicine. 2025. doi:10.1093/jsxmed/qdaf067
BibTeX
@article{AlMitwalli2025,
author = {Al-Mitwalli, Abdullah and Holden, Fiona and Di Giovanni, Angelo and Gobbo, Andrea and Shah, Mohammad and Chiriaco, Giovanni and Sangster, Pippa and Ralph, David and Lee, Wai Gin},
title = {Intracavernosal injection of aviptadil and phentolamine for refractory erectile dysfunction},
journal = {The Journal of Sexual Medicine},
year = {2025},
doi = {10.1093/jsxmed/qdaf067}
}
EUVIMED